Esperance Pharmaceuticals Announces Initiation Of Clinical Studies Of Its Novel Membrane-disrupting Agent, EP-100, In Patients With Cancer Drug discovery and development company Esperance Pharmaceuticals announced that it has begun enrollment and dosing of patients in a Phase 1 study of EP-100 in patients with advanced solid tumors. EP-100, the lead candidate from Esperance's Cationic Lytic Peptide (CLYP(TM)) platform technology, is a targeted membrane-disrupting peptide (tMDP) designed to seek and destroy cancer cells that over-express luteinizing hormone releasing hormone (LHRH) receptors on their surfaces.
Source: www.medicalnewstoday.comNovaBay Launches Clinical Study For Non-Antibiotic Treatment Of Impetigo, One Of The Most Common Skin Infections NovaBay(R) Pharmaceuticals, Inc. (NYSE-Amex: NBY), a clinical stage company developing novel anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral and fungal infections, announced the start of a Phase 2a proof-of-concept study of its lead Aganocide(R) compound NVC-422 in impetigo. NovaBay's partner in the impetigo trial is Galderma, S.A. the world's leading dermatology company.
Source: www.medicalnewstoday.comPhase 3 Trial Of Aflibercept In Metastatic Pancreatic Cancer Discontinued Sanofi-aventis (Euronext: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced the discontinuation of the Phase 3 trial that evaluated aflibercept (VEGF Trap) plus gemcitabine versus placebo plus gemcitabine for the first-line treatment of metastatic pancreatic cancer (VANILLA), based on the recommendations by an Independent Data Monitoring Committee (IDMC).
Source: www.medicalnewstoday.comBritain, France receive first shipment of H1N1 vaccine doses. Britain, France receive first shipment of H1N1 vaccine doses. AFP (8/28) reports, “Britain and France have received their first batches of swine flu vaccine, officials said Thursday, as governments began to arm themselves against a second wave of the pandemic in the northern winter.” Health officials in both countries “said the H1N1 vaccine should win licensing [...]
Source: feedproxy.google.comUPI to Host Newsmaker Forum on Water-related Illnesses United Press International will host Our Water, a multimedia newsmaker event focused on preventable water-related illnesses, September 23, 2009 from 11am-2pm on the first floor of the Verizon Bldg, 1133 19th St. NW, Washington, DC. (PRWeb Sep 11, 2009)
Read the full story at http://www.prweb.com/releases/2009/09/prweb2863804.htm
Source: www.prweb.comPTC Therapeutics Initiates Registration-Directed Phase 3 Trial Of Ataluren In Cystic Fibrosis PTC Therapeutics, Inc. (PTC) announced the initiation of a Phase 3 trial of ataluren (formerly PTC124(R)), an investigational protein restoration therapy in patients with nonsense mutation cystic fibrosis (nmCF). Patients with CF lack adequate levels of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, a chloride channel necessary for normal function of the lung, pancreas, liver, and other organs.
Source: www.medicalnewstoday.comQueen's $1.8M Study To Test Canadian Exercise Guidelines How hard and for how long should you exercise in order to shed excess abdominal fat and reduce your risk of cardiovascular disease? That question - of particular interest to the more than 60 per cent of Canadians who are overweight or obese - will be investigated over the next three years by researchers at Queen's University in a new $1.8-million study funded by the Canadian Institutes of Health Research (CIHR).
Source: www.medicalnewstoday.comHealth Biotech Firms With Developing Country Partners Better Postitioned To Innovate, Prosper Collaboration with health biotech companies in developing countries represents a major opportunity for companies in developed countries to strengthen their market reach and innovation potential, acording to the results of a new study.
Source: www.medicalnewstoday.comUnisourceDirect™ Web Site Now Offering Products to Maintain a Healthy School Environment Items Available To Help Control Spread of H1N1 Influenza; Free Shipping To Eligible Customers (PRWeb Sep 11, 2009)
Read the full story at http://www.prweb.com/releases/UnisourceDirect/hand_sanitizers/prweb2861294.htm
Source: www.prweb.com
# posted by Network @ 11:21 PM
